- Home
- REBN vs MTVA Comparison
REBN vs MTVA Comparison
Compare REBN & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- MTVA
- Stock Information
- Founded
- REBN 2015
- MTVA 2014
- Country
- REBN United States
- MTVA United States
- Employees
- REBN N/A
- MTVA N/A
- Industry
- REBN Restaurants
- MTVA
- Sector
- REBN Consumer Discretionary
- MTVA
- Exchange
- REBN Nasdaq
- MTVA NYSE
- Market Cap
- REBN 13.5M
- MTVA 7.1M
- IPO Year
- REBN 2022
- MTVA N/A
- Fundamental
- Price
- REBN $2.51
- MTVA $0.71
- Analyst Decision
- REBN
- MTVA Strong Buy
- Analyst Count
- REBN 0
- MTVA 1
- Target Price
- REBN N/A
- MTVA $12.00
- AVG Volume (30 Days)
- REBN 86.8K
- MTVA 1.5M
- Earning Date
- REBN 03-31-2025
- MTVA 05-20-2025
- Dividend Yield
- REBN N/A
- MTVA N/A
- EPS Growth
- REBN N/A
- MTVA N/A
- EPS
- REBN N/A
- MTVA N/A
- Revenue
- REBN $5,928,533.00
- MTVA N/A
- Revenue This Year
- REBN $335.98
- MTVA N/A
- Revenue Next Year
- REBN N/A
- MTVA N/A
- P/E Ratio
- REBN N/A
- MTVA N/A
- Revenue Growth
- REBN 7.63
- MTVA N/A
- 52 Week Low
- REBN $1.03
- MTVA $0.71
- 52 Week High
- REBN $8.80
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- REBN 36.61
- MTVA N/A
- Support Level
- REBN $2.41
- MTVA N/A
- Resistance Level
- REBN $2.68
- MTVA N/A
- Average True Range (ATR)
- REBN 0.22
- MTVA 0.00
- MACD
- REBN 0.02
- MTVA 0.00
- Stochastic Oscillator
- REBN 16.88
- MTVA 0.00
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.